Heart Retransplantation: A 23-Year Single-Center Clinical Experience

Schnetzler, Bruno; Pavie, Alain; Dorent, Richard; Camproux, Anne-Claude; Léger, Philippe; Delcourt, A; Gandjbakhch, I

doi:10.1016/s0003-4975(98)00058-7

Cited by 73 publications

(57 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study is consistent with the findings of previous studies (10,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) though it reports a lower survival than the international average of RTx survival. Reasons for this discrepancy may be due to the high percentage of early (30 days) RTx in our cohort, which has been demonstrated to significantly predict mortality (19).…”

Section: Discussionsupporting

confidence: 93%

“…Although different surgical and medical options have been proposed to overcome allograft failure such as revascularization, valvular repair, mechanical assistance and new pharmacological regimens (8,(12)(13)(14)(15), heart RTx remains the only definitive management for these patients. Previous studies have demonstrated that outcomes following RTx are inferior to those for primary HTx (10,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). Given the limited number of available donor hearts, the long-term results of this treatment option need to be evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…Several therapeutic interventions including aggressive immunosuppressive therapy, percutaneous transluminal coronary angioplasty, laser myocardial therapy, coronary artery bypass grafting, valvular repair and temporary and long term mechanical circulatory assist devices have been proposed; however, heart retransplantation (RTx) remains the only viable long-term treatment for end-stage cardiac allograft failure (4)(5)(6)(7)(8). Despite annual RTx rates of as high as 6% as reported by the 2017 ISHLT data (9), the literature on RTx is ambiguous with several studies reporting conflicting findings in regards to the survival and viability of this therapy (10,11).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis

Rizvi

Luc

Choi

et al. 2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

Background: Long-term efficacy of heart retransplantation (RTx) for end-stage cardiac allograft failure remains unclear given the limited worldwide experience and is an important question to elucidate given the shortage of donor organs. The aim of this systematic review was to examine the outcomes of RTx in patients with cardiac allograft failure.Methods: Electronic search was performed to identify all studies in the English literature assessing RTx for cardiac allograft failure. All identified articles were systematically assessed for inclusion and exclusion criteria.Results: Eleven studies were included for analysis, with a total of 7,791 patients. A total of 7,446 patients underwent primary heart transplantation (HTx) whereas 345 patients underwent RTx with average time from primary HTx to RTx interval of 5.03 years (95% CI: 3.13-6.94 years). There were 35.2% of patients Conclusions:Patients who underwent heart RTx had a significant lower survival when compared to those who only underwent primary HTx. There were no significant differences in post-transplantation freedom from rejection. Careful patient selection and perioperative care can make heart RTx a viable option for selected recipients.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis

Rizvi

Luc

Choi

et al. 2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

show abstract

“…2,5,14 Retransplantation remains the last therapeutic option for cardiac allograft failure due to progressive CAV. [31][32][33][34][35] Unfortunately, this therapeutic option is limited mostly because of organ shortage and associated with long waiting times. 36 Therefore, bridge to retransplantation and bridge to destination with a ventricular assist device might be lifesaving.…”

mentioning

confidence: 99%

Cardiac Surgery after Heart Transplantation - Elective Operation or Last Exit Strategy?

Goekler

Aliabadi

Salameh

et al. 2016

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Тем не менее ряд ав-торов считает, что отдаленные результаты ретранс-плантации сердца могут быть улучшены [27][28][29][30][31][32][33][34][35][36][37].…”

unclassified

Heart Retransplantation

Саитгареев

Захаревич

Гольц

et al. 2016

RJTAO

View full text Add to dashboard Cite

1 ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздрава России, Москва, Российская Федерация 2 Кафедра трансплантологии и искусственных органов ГБОУ ВПО «Первый МГМУ им. Сеченова» Минздрава России, Москва, Российская Федерация Популяция пациентов с трансплантированным сердцем непрерывно увеличивается. Как следствие, возрастает количество пациентов, нуждающихся в ретрансплантации сердца (РеТС). В данном обзоре литературы представлен анализ результатов опубликованных исследований, посвященных изучению и безопасности РеТС и факторов риска нежелательных событий в периоперационном и отдаленном перио-дах. Результаты опубликованных исследований свидетельствуют о том, что РеТC, являющаяся основным радикальным методом лечения дисфункции сердечного трансплантата, несколько уступает первичной трансплантации сердца (ТС), однако может иметь благоприятный отдаленный прогноз, если будет вы-полняться по показаниям у отдельных групп пациентов. The number of patients with transplanted heart is continuously increasing; therefore, the number of patients requiring heart retransplantation grows. Analysis of the results of published studies focused on safety of cardiac retransplantation and risk factors for adverse events in perioperative, early and late postoperative periods is presented in our review. The results of published studies suggest that heart retransplantation is the main radical treatment option for cardiac allograft dysfunction, but the results of heart retransplantation are slightly worse than those of primary cardiac transplantation. On the other hand, the favorable long-term prognosis after heart retransplantation should be expected in carefully selected recipients.

show abstract

Heart Retransplantation: A 23-Year Single-Center Clinical Experience

Cited by 73 publications

References 8 publications

Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis

Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis

Cardiac Surgery after Heart Transplantation - Elective Operation or Last Exit Strategy?

Heart Retransplantation

Contact Info

Product

Resources

About